-

SubjectWell Receives System and Organization Controls (SOC) 2 Type 2 Certification

The patient access marketplace successfully demonstrates strong data security credentials throughout comprehensive assessment

AUSTIN, Texas--(BUSINESS WIRE)--SubjectWell, the patient access marketplace that connects patients with chronic health conditions to new care options, today announced it has received its System and Organization Controls (SOC) 2 Type 2 certification, a voluntary compliance standard which specifies how organizations should manage customer data. By successfully completing the SOC 2 Type 2 assessment, SubjectWell demonstrates its commitment to the security of the largest, most trusted, direct patient access marketplace.

“Becoming SOC 2 Type 2 certified was no small feat, but as a company built on patient data, we are committed to this essential security framework,” said Fred Martin, CEO, SubjectWell. “I am proud of our technology team for their efforts in receiving this certification, and we will continue to prioritize the protection of our patients’ data.”

Developed by the American Institute of Certified Public Accountants (AICPA), SOC 2 is a highly sought-after security framework based on criteria for security, availability, processing integrity, confidentiality, and privacy. SubjectWell’s Type 2 certification confirms its security framework is operationally effective.

“With 12 million patients registered in our marketplace growing at more than 300,000 monthly, SubjectWell handles a massive volume of sensitive information daily,” said Chris Penney, Vice President of Technology, SubjectWell. “Our sponsor and CRO partners can have confidence that our data management is structured for the security and protection of our patients’ demographic and medical information.”

About SubjectWell

SubjectWell is the patient access marketplace, connecting patients with chronic health conditions to trials and treatments. Since 2012, SubjectWell has been raising awareness of the benefits of clinical research, registering tens of millions of healthcare-motivated patients with known conditions. At SubjectWell, we already have the patients you need. Visit www.SubjectWell.com to find out more.

Contacts

Media Contact
Jillian Hammell
Crowley Webb for SubjectWell
jillian.hammell@crowleywebb.com, 716.844.7237

SubjectWell


Release Versions

Contacts

Media Contact
Jillian Hammell
Crowley Webb for SubjectWell
jillian.hammell@crowleywebb.com, 716.844.7237

More News From SubjectWell

SubjectWell Acquires PatientCentra

AUSTIN, Texas--(BUSINESS WIRE)--SubjectWell, the patient access marketplace that connects patients with chronic health conditions to new care options, today announced the acquisition of PatientCentra, an MD Connect, Inc. business. Located in Waltham, MA, PatientCentra offers full-service, global patient recruitment capabilities plus an in-house agency for the development of tailored, patient-centric recruitment journeys. Through this acquisition, SubjectWell now serves the patient recruitment n...

SubjectWell Expands Executive Leadership to Realize Growth Strategy

AUSTIN, Texas--(BUSINESS WIRE)--SubjectWell, the largest engagement platform for matching patients with chronic health conditions to new care options, announced that clinical industry veteran Fred Martin has joined SubjectWell as CEO. After an extensive year-long search for a proven leader with the right combination of experience accelerating technical solutions and building investor relations, Fred’s addition to SubjectWell’s senior leadership team allows co-founder and previous CEO Ivor Clark...

US Tech Startup SubjectWell Secures $35 Million in Investment, Focuses Growth in South African Operations

AUSTIN, Texas--(BUSINESS WIRE)--SubjectWell, the largest engagement platform for matching patients with chronic health conditions to new care options in clinical trials, recently announced a R630 Million ($35 million USD) Series B funding round led by Asset Management Ventures. This new investment will accelerate the growth of SubjectWell's existing clinical trial patient recruitment efforts, expand its support of cancer research and fund production of its awareness initiatives for post-approva...
Back to Newsroom